Corebridge Financial Inc. Has $5.78 Million Position in West Pharmaceutical Services, Inc. (NYSE:WST)

Corebridge Financial Inc. decreased its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 7.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,657 shares of the medical instruments supplier’s stock after selling 1,344 shares during the period. Corebridge Financial Inc.’s holdings in West Pharmaceutical Services were worth $5,784,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Fiera Capital Corp increased its position in shares of West Pharmaceutical Services by 13.2% during the fourth quarter. Fiera Capital Corp now owns 140,893 shares of the medical instruments supplier’s stock worth $46,151,000 after acquiring an additional 16,418 shares in the last quarter. Trust Point Inc. increased its holdings in West Pharmaceutical Services by 321.0% during the 4th quarter. Trust Point Inc. now owns 3,183 shares of the medical instruments supplier’s stock worth $1,043,000 after purchasing an additional 2,427 shares in the last quarter. Savant Capital LLC raised its stake in shares of West Pharmaceutical Services by 15.0% in the fourth quarter. Savant Capital LLC now owns 1,003 shares of the medical instruments supplier’s stock worth $329,000 after purchasing an additional 131 shares during the last quarter. Nomura Asset Management Co. Ltd. raised its stake in shares of West Pharmaceutical Services by 22.4% in the third quarter. Nomura Asset Management Co. Ltd. now owns 130,345 shares of the medical instruments supplier’s stock worth $39,124,000 after purchasing an additional 23,850 shares during the last quarter. Finally, Sanctuary Advisors LLC lifted its holdings in shares of West Pharmaceutical Services by 80.9% in the third quarter. Sanctuary Advisors LLC now owns 6,800 shares of the medical instruments supplier’s stock valued at $2,153,000 after purchasing an additional 3,042 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Trading Down 1.8 %

Shares of WST stock opened at $222.08 on Friday. The company has a quick ratio of 2.23, a current ratio of 2.79 and a debt-to-equity ratio of 0.08. The firm has a market cap of $16.06 billion, a P/E ratio of 33.20, a PEG ratio of 6.74 and a beta of 1.09. The company has a 50 day moving average of $263.98 and a 200-day moving average of $297.82. West Pharmaceutical Services, Inc. has a 12-month low of $197.01 and a 12-month high of $396.75.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, February 13th. The medical instruments supplier reported $1.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.75 by $0.07. West Pharmaceutical Services had a return on equity of 18.60% and a net margin of 17.03%. The business had revenue of $748.80 million during the quarter, compared to the consensus estimate of $739.59 million. Sell-side analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 7th. Shareholders of record on Wednesday, April 30th will be given a dividend of $0.21 per share. The ex-dividend date of this dividend is Wednesday, April 30th. This represents a $0.84 dividend on an annualized basis and a yield of 0.38%. West Pharmaceutical Services’s dividend payout ratio is presently 12.56%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. KeyCorp decreased their price target on West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Bank of America increased their target price on shares of West Pharmaceutical Services from $350.00 to $355.00 and gave the company a “buy” rating in a report on Friday, December 13th. Citigroup began coverage on shares of West Pharmaceutical Services in a report on Wednesday, January 8th. They set a “buy” rating and a $400.00 price target on the stock. StockNews.com lowered shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Thursday, February 27th. Finally, Deutsche Bank Aktiengesellschaft upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 target price on the stock in a research note on Friday, February 14th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $332.50.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.